Mirion Technologies, Inc. MIR
We take great care to ensure that the data presented and summarized in this overview for Mirion Technologies, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MIR
View all-
Vanguard Group Inc Valley Forge, PA23.3MShares$493 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD20.7MShares$439 Million0.2% of portfolio
-
Black Rock Inc. New York, NY15.8MShares$335 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X08.59MShares$182 Million0.07% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx8.06MShares$171 Million2.3% of portfolio
-
Dimensional Fund Advisors LP Austin, TX7.36MShares$156 Million0.03% of portfolio
-
Brown Advisory Inc5.56MShares$118 Million0.12% of portfolio
-
State Street Corp Boston, MA5.14MShares$109 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA4.74MShares$100 Million0.01% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL4.15MShares$87.9 Million0.26% of portfolio
Latest Institutional Activity in MIR
Top Purchases
Top Sells
About MIR
Mirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, Netherlands, Estonia, and Japan. It operates through two segments, Medical and Industrial. The medical segment offers radiation oncology quality assurance and dosimetry solutions; patient safety solutions for diagnostic imaging and radiation therapy centers; radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy; and radionuclide therapy products for nuclear medicine applications, such as shielding, product handling, medical imaging furniture, and rehabilitation products. This segment supports applications in medical diagnostics, cancer treatment, practitioner safety, and rehabilitation. The Industrial segment focuses on addressing critical radiation safety, measurement, and analysis applications; and provides personal radiation detection, identification equipment, and analysis tools. The company's products and solutions also include nuclear medicines, dosimeters, contamination and clearance monitors, reactor instrumentation and control equipment and systems, medical and industrial imaging systems and related accessories, alpha spectroscopy instruments, alpha/beta counting instruments, and gamma spectroscopy detector systems; and electrical penetration, cancer diagnostics, software, and other services. It serves hospitals, clinics and urgent care facilities, dental and veterinary offices, radiation treatment facilities, OEMs for radiation therapy, laboratories, military organizations, government agencies, industrial companies, power and utility companies, reactor design firms, and NPPs. The company was formerly known as Global Monitoring Systems, Inc. and changed its name to Mirion Technologies, Inc. in January 2006. Mirion Technologies, Inc. was incorporated in 2005 and is headquartered in Atlanta, Georgia.
Insider Transactions at MIR
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 30
2025
|
John W Kuo Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,024
+1.3%
|
-
|
Jun 30
2025
|
Jody Markopoulos Director |
BUY
Grant, award, or other acquisition
|
Direct |
880
+1.17%
|
-
|
Jun 25
2025
|
Brian Schopfer Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
75,000
-7.54%
|
$1,575,000
$21.0 P/Share
|
Jun 25
2025
|
Brian Schopfer Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
75,000
-13.05%
|
-
|
Jun 25
2025
|
Brian Schopfer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+7.01%
|
-
|
May 21
2025
|
Brian Schopfer Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
75,000
-7.54%
|
$1,350,000
$18.27 P/Share
|
May 21
2025
|
Brian Schopfer Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
75,000
-11.54%
|
-
|
May 21
2025
|
Brian Schopfer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+7.01%
|
-
|
May 21
2025
|
Lawrence D Kingsley Director |
SELL
Open market or private sale
|
Indirect |
500,000
-100.0%
|
$8,500,000
$17.95 P/Share
|
May 15
2025
|
Robert Cascella Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,977
+12.99%
|
-
|
May 15
2025
|
Kenneth Bockhorst Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,977
+9.11%
|
-
|
May 15
2025
|
Sheila Rege Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,977
+15.81%
|
-
|
May 15
2025
|
Lawrence D Kingsley Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,977
+11.52%
|
-
|
May 15
2025
|
Jody Markopoulos Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,977
+9.82%
|
-
|
May 15
2025
|
John W Kuo Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,977
+9.43%
|
-
|
May 15
2025
|
Steven W. Etzel Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,977
+9.06%
|
-
|
May 14
2025
|
Loic Eloy Nuclear & Safety President |
BUY
Grant, award, or other acquisition
|
Direct |
31,273
+15.94%
|
-
|
May 14
2025
|
Brian Schopfer Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
29,149
-3.07%
|
$495,533
$17.43 P/Share
|
May 14
2025
|
Brian Schopfer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,154
+6.43%
|
-
|
May 14
2025
|
Thomas D Logan Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
89,430
-2.15%
|
$1,520,310
$17.43 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 812K shares |
---|---|
Conversion of derivative security | 8.1M shares |
Bona fide gift | 1.05M shares |
Bona fide gift | 4.21M shares |
---|---|
Open market or private sale | 765K shares |
Sale (or disposition) back to the issuer | 150K shares |
Payment of exercise price or tax liability | 382K shares |
Conversion of derivative security | 48.4K shares |